Improved Diagnostics and Monitoring of Polymyalgia Rheumatica

  • End date
    Oct 1, 2023
  • participants needed
  • sponsor
    Kresten Krarup Keller
Updated on 17 February 2021
general symptoms
positron emission tomography/computed tomography


Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects. PMR is an exclusion diagnosis, and methods to diagnose and monitor the disease are lacking.

Objective: To investigate if ultrasound and PET/CT can be used to diagnose and monitor PMR. In addition, the importance of prednisolone induced adrenal insufficiency is investigated.

Methods: It is a prospective observational study in patients suspected of PMR. Patients diagnosed with PMR continue in the study. Ultrasound and PET/CT are performed at baseline, after 8 weeks on prednisolone, and after 10 weeks during a short prednisolone break. Adrenal insufficiency is investigated five times throughout the study. After one year the PMR diagnosis is confirmed.

Condition Adrenal Insufficiency, Giant Cell Arteritis, Polymyalgia Rheumatica, Polymyalgia Rheumatica (PMR), temporal arteritis, hypoadrenalism, adrenal cortical insufficiency
Treatment PET/CT
Clinical Study IdentifierNCT04519580
SponsorKresten Krarup Keller
Last Modified on17 February 2021


Yes No Not Sure

Inclusion Criteria

Patients suspected of PMR
Age above 50
Pain of the proximal muscles

Exclusion Criteria

Peroral, intraarticular, intramuscular and dermal application of glucocorticoids within the last 3 month
Previous prednisolone treatment for GCA/PMR
Unable to give consent
Symptoms of GCA (headache, jaw claudication, vision disturbances)
Active malignant cancers within the last 5 years (except basal cell carcinoma)
Other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout)
Uncontrolled diseases (eg severe active astma, cardiac disease with NYHA class IV)
Treatment with peroral oestrogens, aminogluthethimid, trilostan, ketoconazole, fluconazol, etomidate, phenobarbital, phenytoin, rifampicin, metyrapon, mitotane
Known primary or secondary adrenal insufficiency
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note